Audion Therapeutics is a private biopharmaceutical company dedicated to the discovery and development of drugs and delivery technologies for the treatment of diseases affecting the ear, including hearing loss. Audion’s headquarters are in Amsterdam, The Netherlands and our labs are in Cambridge, MA, USA.
Our mission is to improve the lives of patients suffering from the most prevalent forms of hearing. In 2015, almost 7% of the world’s population, approximately half a billion people, had disabling hearing loss. In 2015 hearing loss was the 4th leading cause of years lived with disability (YLDs). The reach of hearing loss extends far beyond sensory impairment in young as well as older people. Yet no drug treatments currently exist. We are committed to discovering effective therapies through our world-leading research into inner ear cellular biology and physiology. To achieve our goals we collaborate with leading research institutions and companies both in the EU and US.
Clinical development of LY3056480
Audion is coordinator of the REGAIN Project funded bij the European Union through the Horizon 2020 program. REGAIN started in 2015 to take a LY3056480, a drug identified by Audion into clinical development. Preclinical development was completed in 2017 and a positive clinical phase 1 study has been completed at the end of 2018 and the drug has been shown to be safe. Recruitment of patients for phase 2 commenced in January 2019 in Tübingen, Athens and London and recruitment has now been concluded, study finalised and data being analysed.
Participation in future clinical studies
Patients interested to participate in future, follow-on clinical studies for Audion’s hair regeneration drug LY3056480 please follow the news on this website and other public channels.